Bernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to treat high-risk renal cell carcinoma, which validate the 16-gene Recurrence Score in patients with stage III disease. (Abstract 4508)
Xuesong Han, PhD, of the American Cancer Society, discusses the Affordable Care Act and her study findings showing how implementation of the law is associated with a shift to early-stage diagnosis for all screenable cancers except prostate cancer (likely due to Task Force recommendations against routine screening). (Abstract 6521)
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Clifford A. Hudis, MD, ASCO’s current CEO, discuss the state of cancer care and the challenges that lie ahead.
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.
